Investor Presentation

GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 4th November 2026 BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sirs, Subject: Presentation of Analyst / Institutional Investor Meetings Pursuant to Regulation 30 read with Part A of Schedule Ill of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the presentation to be made in Investors / Analysts Call and the same is also being uploaded on the website of the Company. Thanking you, Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary CIN: L24239MH1924PLC001151 GlaxoSmithKline Pharmaceuticals Limited gsk.com Bhushan Akshikar, Managing Director Mr. Bhushan Akshikar has been the MD of GSK India since Q3 2022. He brings over 15 years of leadership experience within GSK in key roles across India, Middle East, Russia CIS & Africa region. Prior to joining GSK, Bhushan spent 15 years with Johnson & Johnson, in local and regional positions in India, S. Korea and Belgium. Ronojit Biswas, Chief Financial Officer Mr. Ronojit Biswas has been the CFO of GSK India since April 2026. He brings over 25 years of experience across global finance roles, spanning India, Vietnam, Singapore, Brazil and the UK. Prior to this role, Ronojit served as Senior Finance Director – Global Product Strategy for the General Medicines Therapy Area and has previously been Regional Controller (International) and CFO for GSK’s Brazil and Vietnam businesses. GSK India’s Key Focus areas to drive growth aligned to global priorities Deliver Simplify how Accelerate growth we work Established portfolio – deliver Reduce complexity, focus resources on Focus on innovation & accelerate competitive performance; what matters most and embrace launch of pipeline products Innovative portfolio – deliver ambition AI/tech to drive agility IPM Q2 FY27 grew at 14.7%, GSK continued its momentum IPM sees growth largely on account Within Acute, key therapies like AI, Respi of price. grew at 7% & 5% resp. 6.1% 5.0% 3.6% 14.7% Jul-Sep’26 IPM Gr. Chronic grew better vs acute increasing its industry contribution Acute 60% 13% Chronic 40% % Growth MNCs grew at par with Indian players for the quarter Indian 84% 15% MNCs 16% 15% % Growth 04 November 2026 4 ecirP emuloV IN GSK’s Rep market grew at 11% with Gen GSK’s performance in metro class and Med outperforming the market specialties outgrew the market GSK portfolio* has maintained its leadership with 25% share in rep 13.3 CARDIAC 17.5 market 10.5 AI 7.1 Rep mar 11% 12.2% 10.5 GASTRO 10 GSK portfolio 12% 33% 8.7% 6% GSK 31% 9.0 ANTI DIABETIC 19.3 Price: 3.5%, Vol: 2.3%, NI: 5.3% 20% 16% 8.7 PAIN 16.5 GSK Gen Med portfolio* has maintained its leadership with 25% Metros T1 T2-6 Rural 7.6 RESPIRATORY 5.3 share in rep market IPM 32% 32% 20% 16% (-1.5%) (+1.6%) (+3%) (-0.6%) 7.5 VIT/MIN/NUT 18.5 Rep mar 8% GPs continue to dominate with 40% Rxns 6.8 DERMA 14.2 GSK Ged Med volume and growth faster than Specialty and 11% Super specialty Rxns portfolio 6.0 NEURO / CNS 15.2 Price: 3.4%, Vol: 0.9%, NI: 3.9% 5.0% 5.1% 4.1% 4.7 GYNAEC. 14.9 GSK Vx portfolio* has maintained its leadership with 26% share in 1.5 HORMONES 9.3 rep market GSK 1.5 VACCINES 24.8 Rep mar 32% 40% 36% 24% GSK Vx 22% portfolio GP Specialty Super Spec % Contri % Value Growth Price: 3.4%, Vol: 12.7%, NI: 16.3% IPM 45% (4.7%); 43% (5.0%%) ; 12% (3%) Source: IQVIA Sep’26 dataset (MQT); *includes all Gen Med & Vaccine brands except GoA portfolio & the discontinued brands GSK’s key brands remained competitive in the market in Q2 FY27 GENERAL MEDICINES VACCINES SPECIALTY Gen Meds1 market share improved (+2.1% Established Vaccines continues to lead the Building equity in the 1 2 4 Unit MS gain, Unit EI 105); key brands overall Vx market with 21.5% Val MS2 Unit EI Respiratory Segment delivered competitive performance 103 & Val EI 100 MS Q1 FY26 Q1 FY27 Val 26.3 26.7 Brand Unit EI Unit MS (G/L) Unit Gr Unit 31.7 33.2 (Q2 FY27) (Q2 FY27) (Q2 FY27) Fluarix 130 22.5% (5.2%) 65.3% New Patient Update 4,000+ Severe asthma Havrix 100 33.8% (0.02%) 16.3% patients benefitted IH 98 45.5% (-0.7%) 21.9% Boostrix 112 32.9% (3.6%) 21.0% Brand Unit EI Unit MS (G/L) Unit Gr 3 Establishing adult immunization as a 5 Strong foundation in Oncology (Q2 FY27) (Q2 FY27) (Q2 FY27) category through Shingrix; driving 2026 Augmentin 105 18.9% (1.0%) 8.2% growth through the CVMD opportunity Calpol 110 34.0% 16.9% (3.0%) 2.6k Rxers for (39% YOY growth) T-Bact 101 47.8% (0.6%) 12.2% New Patient Update Eltroxin 94 20.8% -2.2% (-1.3%) Ceftum 101 23.9% 4.3% (0.3%) Touchpoints 7.9M+ Unique HCPs reached 365K+ HCP / HCO engagement 3.3K+ Neosporin 103 31.4% 16% (F2F + Digital) (F2F + Digital) Events (0.9%) Dist. Brands3 99 39.7% 5.2% (-0.2%) Source: IQVIA Sep'26 dataset (MQT), Internal data; 1excludes GOA; 2 MAT Val MS; 3 Distributed brands includes the GoApptiv portfolio 5 Financial Highlights : Q2 FY 26-27 (Standalone) Delivering growth with continued portfolio transformation Revenue EBITDA PAT (before exceptional) Q2 H1 Q2 H1 Q2 H1 ₹1180cr ₹2104cr ₹400cr ₹693cr ₹335cr ₹588cr Growth +21% Growth +18% Margin: 34% (-50 bps) Margin: 33% (+10 bps) Margin: 29% (+260 bps) Margin: 28% (+230 bps) Growth +20% Growth +18% Growth +33% Growth +29% Q2 Revenue growth +21% Q2 EBITDA margin -50 bps (YoY) Q2 PAT margin +260 bps (YoY) Sales growth driven by execution excellence; and EBITDA moderated slightly, primarily due to a PAT margin stepped up on account of interest continued evolution of innovative portfolio marginal impact from gross margins on income tax refund received during the quarter further aided by favorable base effect from PY Gross margin dilution due to currency EPS for Q2 @ 19.76 (+32%) Innovation* portfolio accounts for 7% (PY 3%) of depreciation and higher input costs partially total sales. Building momentum with Oncology offset by price increases Sustained focus to strengthen and optimize the launches, Adult Vx & New respiratory balance sheet SG&A as a % of sales reduces by 1% on cost General medicines growth led by brands efficiencies Augmentin, Calpol, Neosporin and T-Bact Pead Vaccines continued leadership in the self pay private pediatric market Shingrix doubles in Sales driven by HCPs and HCOs engagement to shape the category * Innovation = Oncology (Jemperli + Zejulo) + New Respiratory (Nucala + Trelegy) + Adult Vaccines (Shingrix) Source: GSK Standalone reported data Consistent competitive performance & profitability improvement with portfolio transformation 35.9 35.2 34.4 33.9 34.3 31.7 31.9 30.7 31.2 28.5 28.3 24.3 22YF 32YF 42YF 42YF 52YF 52YF 52YF 52YF 62YF 62YF 62YF 62YF 72YF 72YF Improving profitability Portfolio transformation EBITDA Margins% Category growth Market share % * Market share of Key promoted brands in its rep market; Key promoted brands - Augmentin, Calpol, Ceftum, T-bact, CCM, Cobadex CZS, Eltroxin, Tenovate,Neosporin, Supacef noitavonnI Est. Vx 27.9 28 27.6 27.4 27.8 27.4 27.6 27.8 26.5 27.1 26.3 Key promoted brands Source: Internal data till Mar 2026; IQVIA Jun’26 42YF 42YF 52YF 52YF 52YF 52YF 62YF 62YF 62YF 62YF 72YF Upcoming Launches Competitive performance gggssskkk...cccooommm End of Presentation